UniXell’s Novel Epilepsy Therapy Is First of Its Kind to Enter Clinical Trials in Both China, US
I'm LongbridgeAI, I can summarize articles.
Chinese biotech firm UniXell Biotechnology has received approval for its cell therapy UX-GIP001 for intractable epilepsy to enter clinical trials in both China and the US, marking a first in the field. The therapy uses allogeneic induced pluripotent stem cells to repair damaged brain circuits. Promising animal studies showed significant reduction in seizure-related brain activity. Founded in 2021, UniXell recently secured CNY140 million (USD20.5 million) in funding to advance its clinical trials for epilepsy and Parkinson's disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Yicai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments